MENU
+Compare
PRRUF
Stock ticker: OTC
AS OF
Sep 15 closing price
Price
$0.19
Change
-$0.00 (-0.00%)
Capitalization
409.48M

PRRUF Immutep Ltd. Forecast, Technical & Fundamental Analysis

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease... Show more

PRRUF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PRRUF with price predictions
Feb 03, 2026

Momentum Indicator for PRRUF turns positive, indicating new upward trend

PRRUF saw its Momentum Indicator move above the 0 level on January 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator turned positive. In of the 45 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The 10-day RSI Indicator for PRRUF moved out of overbought territory on January 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for PRRUF turned negative on January 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at .

PRRUF broke above its upper Bollinger Band on December 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PRRUF entered a downward trend on February 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PRRUF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.736) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRRUF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PRRUF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
264 George Street
Phone
+61 283157003
Employees
24
Web
https://www.immutep.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGFTX10.410.15
+1.46%
Russell Inv Global Infrastructure M
BIPIX71.690.25
+0.35%
ProFunds Biotechnology UltraSector Inv
FEYCX30.46N/A
N/A
Fidelity Advisor Asset Manager 85% C
RYIMX23.85-0.09
-0.38%
Guggenheim Multi-Hedge Strategies I
PXEAX21.36-0.12
-0.56%
Impax Global Environmental Markets A

PRRUF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PRRUF has been loosely correlated with IMMP. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PRRUF jumps, then IMMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRRUF
1D Price
Change %
PRRUF100%
N/A
IMMP - PRRUF
43%
Loosely correlated
+4.76%
CALC - PRRUF
24%
Poorly correlated
-25.56%
PHGUF - PRRUF
21%
Poorly correlated
N/A
PVCT - PRRUF
11%
Poorly correlated
+3.53%
OXBDF - PRRUF
9%
Poorly correlated
-4.66%
More